Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Panag Pharma Inc. currently maintains a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action, which is being reviewed by 1 distinct examiner. This concentration suggests a focused prosecution strategy for their current intellectual property efforts. The involvement of 1 distinct art unit further emphasizes the specialized nature of the pending application.
ATKINSON, JOSHUA ALEXANDER is the busiest examiner for the portfolio, currently overseeing 1 pending office action. Because this pending action represents the entirety of the company's active office actions, the prosecution trajectory is tied to the specific tendencies of the assigned examiner. For a company in the Biotechnology & Pharmaceuticals sector, having 1 distinct examiner and 1 distinct art unit involved in the prosecution allows for a narrow response strategy. This lack of diversity in examiners means the outcome of the current portfolio's pending status depends entirely on the interactions with ATKINSON, JOSHUA ALEXANDER.
Practitioners can focus their resources on understanding this examiner's history within the art unit to optimize their approach. The alignment of the busiest examiner's workload with the total 1 pending office action simplifies the management of the portfolio's current legal standing. This focused environment provides a clear path for the company's intellectual property goals. Understanding the tendencies of the assigned examiner will be important for the prosecution process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ATKINSON, JOSHUA ALEXANDER | 1 | 52.4% | +26.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18558909 | TOPICAL LIPOSOME POLYPHENOL COMPOSITIONS FOR TREATING AND PREVENTING VARIOUS SKIN DISORDERS AND METHODS OF PREPARATION THEREOF | ATKINSON, JOSHUA ALEXANDER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18558909 | TOPICAL LIPOSOME POLYPHENOL COMPOSITIONS FOR TREATING AND PREVENTING VARIOUS SKIN DISORDERS AND METHODS OF PREPARATION THEREOF | ATKINSON, JOSHUA ALEXANDER | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18558909 | TOPICAL LIPOSOME POLYPHENOL COMPOSITIONS FOR TREATING AND PREVENTING VARIOUS SKIN DISORDERS AND METHODS OF PREPARATION THEREOF | ATKINSON, JOSHUA ALEXANDER | 1626 | §101§102§103§112DP | Non-Final OA | — | Pending | Nov 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial